SWOG clinical trial number
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Open
Phase
Accrual
0%
Abbreviated Title
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Activated
12/26/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS
Research committees
Gastrointestinal Cancer
Treatment
Panitumumab
Patient Study Materials
Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary
Other Clinical Trials
SWOG Clinical Trial Number
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
12/26/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Accrual
36%
Open
Phase
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase